NasdaqGM:ANIPPharmaceuticals
What ANI Pharmaceuticals (ANIP)'s Recall, Raised Guidance and Buybacks Could Mean For Shareholders
In May 2026, ANI Pharmaceuticals voluntarily initiated a Class II recall of 3,964 cartons of Estradiol Gel 0.1% across the US after the FDA reported defective packets that were empty or partially filled.
At the same time, the company reported strong first-quarter 2026 results, raised its full-year revenue guidance to between US$1.08 billion and US$1.14 billion, and introduced a US$100 million share repurchase program, highlighting management’s confidence despite operational issues.
We’ll...